About PharmaIN
PharmaIN is a company based in Bothell (United States) founded in 2001. PharmaIN has raised $1.5 million across 21 funding rounds from investors including HHS. PharmaIN offers products and services including PHIN-214 and Proprietary Peptide Drugs. PharmaIN operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Bothell, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pharmain Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.5 M (USD)
in 21 rounds
-
Latest Funding Round
$1.99 M (USD), Grant
Jun 01, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PharmaIN
PharmaIN offers a comprehensive portfolio of products and services, including PHIN-214 and Proprietary Peptide Drugs.
Therapy for in-home treatment of liver disease and cancer.
Drugs designed for in-home management of chronic diseases like cirrhosis.
People of PharmaIN
Unlock access to complete
Funding Insights of PharmaIN
PharmaIN has successfully raised a total of $1.5M across 21 strategic funding rounds. The most recent funding activity was a Grant round of $1.99 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PharmaIN
PharmaIN has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for PharmaIN
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PharmaIN
Investment portfolio details for PharmaIN
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PharmaIN
Detailed financials for PharmaIN
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharmain Comparisons
Peer comparison for PharmaIN
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PharmaIN
PharmaIN operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of PharmaIN
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharmain
Complete news archive for PharmaIN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PharmaIN
PharmaIN was founded in 2001 and raised its 1st funding round 3 years after it was founded.
PharmaIN is headquartered in Bothell, United States. It is registered at Bothell, Washington, United States.
PharmaIN is a funded company, having raised a total of $1.5M across 21 funding rounds to date.
Founded in 2001 and based in Bothell, United States, PharmaIN operates in the biotechnology sector. Proprietary technology platforms, including Protected Graft Copolymer (PGC) and various core binding moieties, are utilized to enhance active pharmaceutical ingredients and enable drug delivery. Preclinical products in development include PHIN-1138 for congestive heart failure, PHIN-1722 for diabetes and obesity, PHIN-438 for auto-immune disease, and PHIN-103 for ascites and hepato-renal syndrome.
PharmaIN's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
PharmaIN offers PHIN-214 and Proprietary Peptide Drugs.
PharmaIN has 1 investor. Key investors include HHS.